Celularity Inc.
CELU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.02 | -0.01 | 0.05 |
| FCF Yield | -7.73% | -2.12% | -7.35% | 3.31% |
| EV / EBITDA | -9.28 | -5.61 | -7.12 | -11.93 |
| Quality | ||||
| ROIC | -24.24% | -27.35% | -13.65% | -10.87% |
| Gross Margin | 61.81% | 8.61% | 68.90% | 59.50% |
| Cash Conversion Ratio | 0.18 | 0.04 | 0.15 | -0.12 |
| Growth | ||||
| Revenue 3-Year CAGR | 40.00% | 43.35% | 47.21% | 44.49% |
| Free Cash Flow Growth | -321.92% | 66.62% | -294.60% | 959.22% |
| Safety | ||||
| Net Debt / EBITDA | -5.05 | -3.34 | -4.49 | -7.09 |
| Interest Coverage | 8.73 | -8.16 | -4.30 | -5.12 |
| Efficiency | ||||
| Inventory Turnover | 0.79 | 1.19 | 0.57 | 1.36 |
| Cash Conversion Cycle | -868.04 | -168.23 | -315.54 | -151.94 |